Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of EEC fusion protein skin test in healthy adults and TB patients
NCT06224608Phase 1Completed
- Sponsor
- Chengdu Coen Biotechnology
- Start
- Jan 2023
- Primary completion
- May 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of EEC in Tuberculosis (TB) (2 arms), sponsored by Chengdu Coen Biotechnology. Primary endpoints: Incidence of adverse events (AEs) at 28 days, Incidence of abnormal blood routine, blood biochemistry, urine routine, and electrocardiogram detection indexes at 3 days and 2 more. Started Jan 2023; status: completed.
02
Drugs
EEC
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06224608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06224608.